Your genes may determine if diabetes drug works

NCT ID NCT06256419

Recruiting now Knowledge-focused Sponsor: The Affiliated Hospital of Xuzhou Medical University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how a person's genes influence their response to GLP-1 RA drugs (like exenatide and liraglutide) for type 2 diabetes. Researchers will analyze blood samples from 300 patients to find genetic markers that predict whether the drug lowers blood sugar and weight. The goal is to personalize diabetes treatment based on genetics.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLP-1 receptor agonists (exenatide, liraglutide)
What this could lead to: If successful, this could help doctors predict which type 2 diabetes patients will benefit most from GLP-1 RA drugs, leading to more personalized treatment.
What could go wrong: This is a retrospective study, not a controlled trial, so it can show links but not prove cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SUSCEPTIBILITY, GENETIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inherited disease susceptibility type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SUSCEPTIBILITY, GENETIC TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

China, Jiangsu, Department of Endocrinology
RECRUITING

Xuzhou, China, 221006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.